Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 96-108

  Jungheim, Louis N ^a   Shepherd, Timothy A ^a   Baxter, Angela J ^a   Burgess, Jeffrey ^a   Hatch, Steven D ^a   Lubbehusen, Penny ^a   Wiskerchen, MaryAnn ^a   Muesing, Mark A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DEXTRO AMINO ACID; INDINAVIR; LIGAND; N [1 BENZYL 3 [2 [(TERT BUTYLAMINO)CARBONYL]PHENYL] 2 HYDROXYPROPYL] 2 [(METHYLSULFONYL)AMINO] 3 (2 NAPHTHYLSULFINYL)PROPIONAMIDE; N [1 BENZYL 3 [2 [(TERT BUTYLAMINO)CARBONYL]PHENYL] 2 HYDROXYPROPYL] 2 [(METHYLSULFONYL)AMINO] 3 [(1 METHYL 5 TETRAZOLYL)SULFINYL]PROPIONAMIDE; N [1 BENZYL 3 [2 [(TERT BUTYLAMINO)CARBONYL]PHENYL] 2 HYDROXYPROPYL] 3 [(4 FLUOROPHENYL)SULFINYL] 2 [(METHYLSULFONYL)AMINO]PROPIONAMIDE; N TERT BUTYL 2 [2 HYDROXY 4 PHENYL 3 [[N (2 QUINOLYLCARBONYL)ASPARAGINYL]AMINO]BUTYL]BENZAMIDE; PROTEINASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; RAT;

AMINO ACIDS; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CYSTEINE; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 0030063081     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950576c     Document Type: Article

References (21)

1. Debouck, C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 1992, 8, 153-164. Fairlie, D. P.; West, M. L. Targeting HIV-1 protease: a test of drug design methodologies. Trends Pharmacol. 1995, 16, 67-75.
2. Debouck, C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 1992, 8, 153-164. Fairlie, D. P.; West, M. L. Targeting HIV-1 protease: a test of drug design methodologies. Trends Pharmacol. 1995, 16, 67-75.
3. Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37, 3443-3451 and references cited therein.
4. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Kröhn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248, 358-361.
5. MK-639 was previously known as L-735,524 as described in ref 2.
6. Kaldor, S. W.; Hammond, M.; Dressman, B. A.; Fritz, J. E.; Crowell, T. A.; Hermann, R. A. New dipeptide isosteres useful for the inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett. 1994, 4, 1385-1390.
7. See, for example: Smith, P. L.; Wall, D. A.; Gochoco, C. H.; Wilson, G. (D) Routes of delivery, case studies (5) Oral absorbtion of peptides and proteins. Adv. Drug Delivery Rev. 1992, 8, 253-290. Burton, P. S.; Conradi, R. A.; Hilgers, A. R.; Ho, N. F. H.; Maggiora, L. L. The relationship between peptide structure and transport across epithelial cell monolayers. J. Controlled Release 1992, 19, 87-98.
8. See, for example: Smith, P. L.; Wall, D. A.; Gochoco, C. H.; Wilson, G. (D) Routes of delivery, case studies (5) Oral absorbtion of peptides and proteins. Adv. Drug Delivery Rev. 1992, 8, 253-290. Burton, P. S.; Conradi, R. A.; Hilgers, A. R.; Ho, N. F. H.; Maggiora, L. L. The relationship between peptide structure and transport across epithelial cell monolayers. J. Controlled Release 1992, 19, 87-98.
9. Martin, J. A. Ro 31-8959/003. Drugs Future 1991, 16, 210-212.
10. Dahlem, A. M.; Schreiner, K. M.; Burgess, J. Unpublished observations, Lilly Research Laboratories.
11. Spellmeyer, D. C.; Brown, S.; Stauber, G. B.; Geysen, H. M.; Valerio, R. Endothelin receptor ligands. Multiple D-amino acid replacement net approach. Bioorg. Med. Chem. Lett. 1993, 3, 1253-1256.
12. 50 = 1.0 and 8.5 nM antiviral activity in CEM cells.
13. Schevitz, R. W.; Wery, J.-P.; Clawson, D. K. (Lilly Research Laboratories); Appelt, K. (Agouron Pharmaceuticals, Inc.) Unpublished observations.
14. 3 ligands for inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett. 1994, 4, 1391-1396.
15. (b) For an alternative approach to asparagine replacement, see: Thompson, W. J.; Ghosh, A. K.; Holloway, M. K.; Lee, H. Y.; Munson, P. M.; Schwering, J. E.; Wai, J.; Darke, P. L.; Zugay, J.; Emini, E. A.; Schleif, W. A.; Huff, J. R.; Anderson, P. S. 3′-Tetrahydrofuranylglycine as a novel, unnatural amino acid surrogate for asparagine in the design of inhibitors of the HIV protease. J. Am. Chem. Soc. 1993, 115, 801-803.
16. Rivero, R. A.; Greenlee, W. J.; Patchett, A. A. Sulfones as peptide bond isosteres. Tetrahedron Lett. 1991, 32, 5263-5264.
17. Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Reed, K. L.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A., Marr, J. J.; Mueller, R. A.; Vazquez, M. L.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R. A. Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. J. Med. Chem. 1993, 36, 288-291.
18. Arnold, L. D.; Kalantar, T. H.; Vederas, J. C. Conversion of serine to stereochemically pure β-substituted α-amino acids via β-lactones. J. Am. Chem. Soc. 1983, 107, 7105-7109.
19. Sasaki, N. A.; Hashimoto, C.; Potier, P. A novel approach to the synthesis of optically pure non protein α-amino acids in both L and D configurations from L-serine. Tetrahedron Lett. 1987, 28, 6069-6072.
20. Manetta, J. V.; Lai, M.-H.; Osborne, A. D. Design and Implementation of a Particle Concentration Fluorescence Method for the Detection of HIV-1 Protease Inhibitors. Anal. Biochem. 1992, 202, 10-15.
21. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity. J. Natl. Cancer Inst. 1989, 81, 577-586.